Idenix Pharmaceuticals (NASDAQ: IDIX) issued its quarterly earnings data on Monday. The company reported ($0.17) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.17). The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.74 million.
Several analysts have also recently commented on the stock. Analysts at Robert W. Baird initiated coverage on shares of Idenix Pharmaceuticals in a research note to investors on Monday, February 11th. They set a “neutral” rating and a $5.00 price target on the stock. On a related note, analysts at Wedbush downgraded shares of Idenix Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, January 30th. They now have a $6.00 price target on the stock, down previously from $7.00. Finally, analysts at Bank of America reiterated a “neutral” rating on shares of Idenix Pharmaceuticals in a research note to investors on Monday, January 28th. They now have a $7.00 price target on the stock, up previously from $6.00.
Four analysts have rated the stock with a buy rating, eight have given a hold rating, and one has assigned a sell rating to the stock. The stock currently has an average rating of “hold” and a consensus target price of $5.33.
Idenix Pharmaceuticals (IDIX) traded down 3.08% on Monday, hitting $4.40. Idenix Pharmaceuticals (IDIX) has a 1-year low of $3.35 and a 1-year high of $12.61. The stock’s 50-day moving average is currently $4.73. The company’s market cap is $589.1 million.
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
